NCT03261947View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

August 24, 2020

Study Completion Date

August 24, 2020

Conditions
Metastatic Pancreatic CancerColorectal CancerEsophageal NeoplasmsCarcinoma, Non-small-cell Lung
Interventions
DRUG

TAK-931

TAK-931 hard gelatin capsules

Trial Locations (10)

34232

Sarah Cannon Research Institute, Sarasota

37203

SCRI - Tennessee Oncology - Nashville - Southern Hills Clinic, Nashville

55404

Allina Health Virginia Piper Cancer Institute, Minneapolis

63110

Siteman Cancer Center, St Louis

73104

University of Oklahoma Health Sciences Center, Oklahoma City

80218

Sarah Cannon Research Institute Oncology Research Consortium, Denver

89119

Comprehensive Cancer Centers of Nevada, Las Vegas

98101-2756

Virginia Mason Medical Center, Seattle

277-8577

National Cancer Center Hospital East, Kashiwa

104-0045

National Cancer Center Hospital, Chuo-ku

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY